LEAP2 and obesity due to melanocortin 4 receptor deficiency: However, many issues, such as the efficacy of LEAP2 as a pharmacological target in the treatment of obesity, its possible role in hedonic eating behaviors, and the changes in its levels depending on different types of bariatric surgery, are still poorly understood.